Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | RAB9A | P51151 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | CA12 | O43570 | 2/20 | 0.60 |
| ▸ | CA1 | P00915 | 2/20 | 0.60 |
| ▸ | CA2 | P00918 | 2/20 | 0.60 |
| ▸ | CA9 | Q16790 | 2/20 | 0.60 |
| ▸ | KIF11 | P52732 | 1/20 | 0.58 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.57 |
| ▸ | RELA | Q04206 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.51 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19707622 | 0.90 | RAB9A (0.76) | RAB9AKMT2AMEN1CA12CA1 | |
| SCHEMBL10155599 | 0.85 | ALDH1A1 (0.78) | ALDH1A1RAB9AKMT2AEPHX1SMN1; SMN2 | |
| SCHEMBL12894469 | 0.84 | KIF11 (0.58) | ALDH1A1RAB9AKMT2AMEN1CA12 | |
| SCHEMBL4117858 | 0.82 | RAB9A (0.67) | RAB9AKMT2AMEN1CA12CA1 | |
| SCHEMBL22588926 | 0.82 | RAB9A (0.67) | ALDH1A1RAB9AKMT2AMEN1CA12 | |
| SCHEMBL23343705 | 0.82 | RAB9A (0.62) | RAB9AKMT2AMEN1CA12CA1 | |
| SCHEMBL4105821 | 0.82 | RAB9A (0.67) | ALDH1A1RAB9AKMT2AMEN1CA12 | |
| SCHEMBL4111411 | 0.82 | MEN1 (0.67) | ALDH1A1RAB9AKMT2AMEN1CA12 | |
| SCHEMBL4118082 | 0.81 | RAB9A (0.65) | RAB9AKMT2AMEN1CA12CA1 | |
| SCHEMBL10857107 | 0.80 | ALDH1A1 (0.51) | ALDH1A1RAB9AKMT2AMEN1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029791-B2 | Therapeutic conjugates | TOTUS MEDICINES INC. (US) | 2024-07-09 | — | — | US | disclosed |
| WO-2024086664-A2 | COVALENT INHIBITORS OF WILD-TYPE AND MUTANT PI3K AND METHOD OF USES THEREOF | TOTUS MEDICINES INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| WO-2023183936-A2 | COMBINATION THERAPY OF A PI3K INHIBITOR AND KRAS INHIBITOR AND METHODS OF USE THEREOF | TOTUS MEDICINES INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| US-11673876-B2 | Substituted aminobenzyl heteroaryl compounds as EGFR and/or PI3K inhibitors | MEKANISTIC THERAPEUTICS LLC (US) | 2023-06-13 | — | — | US | disclosed |
| US-20220213054-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | MEKANISTIC THERAPEUTICS LLC (US) | 2022-07-07 | — | — | US | disclosed |
| US-20220202818-A1 | COMBINATION WITH CHECKPOINT INHIBITORS TO TREAT CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-06-30 | — | — | US | disclosed |
| WO-2021055747-A1 | THERAPEUTIC CONJUGATES | TOTUS MEDICINES INC. (US) | 2021-03-25 | — | — | WO | disclosed |
| US-10842791-B2 | Small molecule inhibitors of EGFR and PI3K | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-11-24 | — | — | US | disclosed |
| US-20190167686-A1 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2019-06-06 | — | — | US | disclosed |
| US-10206924-B2 | Small molecule inhibitors of EGFR and PI3K | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-02-19 | — | — | US | disclosed |
| US-20170360788-A1 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2017-12-21 | — | — | US | disclosed |
| CN-104320972-B | Herbicidal composition comprising uracil compound as active ingredient | 东部福阿母韩农株式会社 | 2017-05-24 | — | — | CN | disclosed |
| US-20150166532-A1 | HOST TARGETED INHIBITORS OF DENGUE VIRUS AND OTHER VIRUSES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-06-18 | — | — | US | disclosed |
| US-20130022629-A1 | Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2013-01-24 | — | — | US | disclosed |
| WO-2012052730-A1 | USE OF PI3K INIBITORS FOR THE TREATMENT OF OBESITY, STEATOSIS AND AGEING | CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) | 2012-04-26 | — | — | WO | disclosed |
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-03-22 | — | — | US | disclosed |
| EP-0536316-A4 | ANTIHYPERCHOLESTEROLEMIC BIS-TRIFLUOROMETHYL-SUBSTITUTED IMIDAZOLINES AND DERIVATIVES THEREOF | — | 1993-11-18 | — | — | EP | disclosed |
| EP-0536316-A1 | ANTIHYPERCHOLESTEROLEMIC BIS-TRIFLUOROMETHYL-SUBSTITUTED IMIDAZOLINES AND DERIVATIVES THEREOF | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-04-14 | — | — | EP | disclosed |
| WO-1991019476-A1 | ANTIHYPERCHOLESTEROLEMIC BIS-TRIFLUOROMETHYL-SUBSTITUTED IMIDAZOLINES AND DERIVATIVES THEREOF | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1991-12-26 | — | — | WO | disclosed |
| US-4043796-A | N-METHYL-N-ALKYLTHIO-N*-PHENYL UREA, CEREALS | ROUSSEL UCLAF (FR) | 1977-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10206924-B2 | Small molecule inhibitors of EGFR and PI3K | EGFR, ERBB2, ERBB3 | ALDH1A1 4653/4885RAB9A 546/4885KMT2A 2786/4885 |
| US-20170360788-A1 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | EGFR, ERBB2, ERBB3 | ALDH1A1 4653/4885RAB9A 546/4885KMT2A 2786/4885 |
| US-20150166532-A1 | HOST TARGETED INHIBITORS OF DENGUE VIRUS AND OTHER VIRUSES | RPL17, RPL26, RPL35 | ALDH1A1 3640/4885RAB9A 49/4885KMT2A 3728/4885 |
| US-12029791-B2 | Therapeutic conjugates | CD47, CD44, EPCAM | ALDH1A1 1307/4885RAB9A 1120/4885KMT2A 2318/4885 |
| US-11673876-B2 | Substituted aminobenzyl heteroaryl compounds as EGFR and/or PI3K inhibitors | EGFR, ERBB2, ERBB3 | ALDH1A1 4447/4885RAB9A 193/4885KMT2A 1969/4885 |
| US-20220213054-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | EGFR, ERBB2, ERBB3 | ALDH1A1 4447/4885RAB9A 193/4885KMT2A 1969/4885 |
| US-10842791-B2 | Small molecule inhibitors of EGFR and PI3K | EGFR, ERBB2, ERBB3 | ALDH1A1 4653/4885RAB9A 546/4885KMT2A 2786/4885 |
| US-20190167686-A1 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | EGFR, ERBB2, ERBB3 | ALDH1A1 4653/4885RAB9A 546/4885KMT2A 2786/4885 |
| US-20130022629-A1 | Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof | CD274, PDCD1LG2, PDCD1 | ALDH1A1 380/4885RAB9A 2271/4885KMT2A 3860/4885 |
| US-20220202818-A1 | COMBINATION WITH CHECKPOINT INHIBITORS TO TREAT CANCER | CD274, PDCD1, PDCD1LG2 | ALDH1A1 608/4885RAB9A 1337/4885KMT2A 914/4885 |
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | MTOR, STAT3, SLC14A1 | ALDH1A1 3750/4885RAB9A 1096/4885KMT2A 2921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.